105 related articles for article (PubMed ID: 22262171)
1. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation.
Yim H; Erikson RL
Mol Cell Biol; 2009 May; 29(10):2609-21. PubMed ID: 19289504
[TBL] [Abstract][Full Text] [Related]
3. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
[TBL] [Abstract][Full Text] [Related]
5. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract][Full Text] [Related]
6. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
Murugan RN; Park JE; Kim EH; Shin SY; Cheong C; Lee KS; Bang JK
Mol Cells; 2011 Sep; 32(3):209-20. PubMed ID: 21809214
[TBL] [Abstract][Full Text] [Related]
7. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
Yan F; Liu G; Chen T; Fu X; Niu MM
Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
[TBL] [Abstract][Full Text] [Related]
9. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.
Deeraksa A; Pan J; Sha Y; Liu XD; Eissa NT; Lin SH; Yu-Lee LY
Oncogene; 2013 Jun; 32(24):2973-83. PubMed ID: 22890325
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C
ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973
[TBL] [Abstract][Full Text] [Related]
11. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
12. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
[TBL] [Abstract][Full Text] [Related]
13. Plk1-mediated phosphorylation of Topors regulates p53 stability.
Yang X; Li H; Zhou Z; Wang WH; Deng A; Andrisani O; Liu X
J Biol Chem; 2009 Jul; 284(28):18588-92. PubMed ID: 19473992
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.
Zhou Y; Yan F; Huo X; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795214
[TBL] [Abstract][Full Text] [Related]
15. PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects.
Poyil PK; Siraj AK; Padmaja D; Parvathareddy SK; Thangavel S; Alobaisi K; Diaz R; Begum R; Haqawi W; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Mol Oncol; 2024 Mar; 18(3):691-706. PubMed ID: 38361222
[TBL] [Abstract][Full Text] [Related]
16. Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
Stebbing J; Bullock AJ
Clin Cancer Res; 2024 May; 30(10):2005-2007. PubMed ID: 38470499
[TBL] [Abstract][Full Text] [Related]
17. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.
Nieto-Jiménez C; Alcaraz-Sanabria A; Pérez-Peña J; Corrales-Sánchez V; Serrano-Heras G; Galán-Moya EM; Serrano-Oviedo L; Montero JC; Burgos M; Llopis J; Pandiella A; Ocaña A
Oncotarget; 2017 Mar; 8(12):19478-19490. PubMed ID: 28061448
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition.
Park JE; Kirsch K; Lee H; Oliva P; Ahn JI; Ravishankar H; Zeng Y; Fox SD; Kirby SA; Badhwar P; Andresson T; Jacobson KA; Lee KS
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305037120. PubMed ID: 37603740
[TBL] [Abstract][Full Text] [Related]
19. PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.
Gheghiani L; Wang L; Zhang Y; Moore XTR; Zhang J; Smith SC; Tian Y; Wang L; Turner K; Jackson-Cook CK; Mukhopadhyay ND; Fu Z
Cancer Res; 2021 Mar; 81(5):1293-1307. PubMed ID: 33376114
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4
Zhou D; Hayashi T; Jean M; Kong W; Fiches G; Biswas A; Liu S; Yosief HO; Zhang X; Bradner J; Qi J; Zhang W; Santoso N; Zhu J
Sci Adv; 2020 Jul; 6(29):eaba1941. PubMed ID: 32832623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
